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1. Introduction 
There are about quarter of million patients on chronic renal replacement therapy in Europe, 
and the estimated number of patients with chronic kidney disease, stages 1-4 is about 
tenfold higher. Interestingly, regardless of the initiating cause (infection, autoimmune 
response, chemical insult, radiation or tissue injury etc.), the mechanism of fibrosis is similar 
in the different chronic kidney diseases and characterized by inflammation. In general, the 
damaged glomerular or tubular cells release danger signals (Anders, 2010; McDonald et al., 
2010) and produce chemotactic stimuli, which trigger the rapid recruitment of leukocytes.  
The infiltrating immune and the damaged renal cells then produce high levels of 
proinflammatory cytokines, growth factors, chemokines and adhesion molecules which 
contribute to glomerular/tubular injury, accumulation of further leukocytes and 
myofibroblasts, which are the effector cells of renal fibrosis. However the origin of the 
myofibroblasts is still controversial recent hypotheses suggest that myofibroblasts can 
originate from different renal cells, such as epithelial and endothelial cells, pericytes or the 
bone marrow derived fibrocytes. The thus generated myofibroblasts then serves as the key 
cellular mediator of renal fibrosis. Myofibroblasts have migratory capacity, are resistant to 
apoptosis, produce several growth factors and cytokines and according to our present 
knowledge these cells are the main source of the collagen-I and collagen-III rich extracellular 
matrix in the fibrous tissue. Organ fibrosis is characterized by excessive deposit of 
extracellular matrix (ECM) leading to glomerular sclerosis and renal tubule-interstitium 
fibrosis. The excessive deposition of fibrous tissue replaces healthy kidney tissue; the 
nephrons disappear and the kidney function gradually declines. In this chapter we will 
summarize our knowledge about the role of immune cells and molecular changes leading to 
generation of renal myofibroblasts. 
2. Role of immune system 
Progressive renal diseases always have an inflammatory component, characterized by the 
infiltration of different leukocytes, overexpression of inflammatory genes and release of pro-
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inflammatory cytokines. In the following paragraphs we will summarise the role of the 
different immune cells in the pathomechanism of renal fibrosis. 
2.1 Neutrophil granulocytes 
Neutrophil granulocytes are polymorphonuclear cells, which constitute the majority of 
circulating leukocytes and respond quickly to chemotactic stimuli. They are the first 
immune cells, which migrate to the inflamed tissue and eliminate the pathogens and tissue 
debris by enzymatic degradation or by reactive oxygen species; moreover, they attract and 
activate further immune cells by producing different chemokines and cytokines. These cells 
are generally regarded as short-lived and terminally differentiated leukocytes. Kidney 
injury leads to the rapid influx of neutrophils and subsequent monocyte and other leukocyte 
recruitment (Machida et al., 2010). Damaged renal cells produce different cytokines and 
chemokines (e.g.: interleukin (IL)-8 (Hang et al., 2000; Topley et al., 2005), IL-17 (Kitching et 
al., 2011) macrophage inflammatory protein (MIP)-1, monocyte chemoattractant protein 
(MCP)-1 (Li et al., 2005)) which - among other leukocytes – efficiently attract neutrophils. 
Neutrophils become activated by immune complexes became trapped in the glomerulus or 
through pattern recognition receptors by damage associated or pathogen-associated 
molecular patterns (DAMP/PAMP) signals (like macrophages, see in details later). In 
response to specific stimuli, neutrophils have the capacity to synthesize several factors such 
as extracellular matrix and antimicrobial proteins (defensins), reactive oxygen species, 
cytokines (IL-1-β, tumor necrosis factor (TNF)-α) and chemokines (IL-8, MIPs) that can 
contribute in regulating the inflammatory response (Cassatella, 1999; Sawyer et al., 1989;  
Fantone & Ward, 1985). Neutrophils are able to generate arachidonic acid-derived lipid 
mediators, such as leukotriene B4, which is also a potent chemoattractant for leukocytes 
(Busse, 1998). Neutrophils have been shown to generate prostaglandin E2 and tromboxane 
via the inducible cyclooxigenase 2 pathway (Maloney et al, 1998). Prostaglandine E2 has 
both pro-and anti-inflammatory properties, for example it regulates vascular permeability, 
so contribute the accumulation of immune cells to the target tissue. Many of these cytokine-, 
lipid- and oxygen-derived mediators are regulated by nuclear factor (NF)-κB activation, 
which supports neutrophils in direct pathogen killing (Blackwell et al., 1997). Although 
these important host defense functions, neutrophils also have an destructive capacity and 
can elicit significant tissue damage. For example, in antineutrophil cytoplasmic antibody -
associated diseases immune complexes became trapped on the endothelial surface in the 
vasculature of glomerulus, and the local activation of neutrophils and monocytes may 
disrupt the integrity of tissue architecture (Weidner et al., 2004). Human 
polymorphonuclear cells may be activated by particulate uromodulin (also known as: 
Tamm-Horsfall glycoprotein), which is the most abundant protein excreted in the urine 
under physiological conditions, but its biological function is still not fully understood 
(Rampoldi et al., 2011). Neutrophil-uromodulin interaction in the renal interstitium is 
characterized by the activation of the respiratory burst, as well as by comprehensive 
polymorphonuclear cell degranulations, which lead to marked tissue damage and 
eventually result in interstitial fibrosis (Horton et al., 1990). Ichino et al has been detected a 
marked upregulation of neutrophil-gelatinase associated lipocalin at the mRNA and protein 
levels in a rat model of renal scarring. This molecule has been proposed over the past years 
as emergent biomarkers for the early and accurate diagnosis and monitoring of acute kidney 
injury (Ichino et al., 2010). After they completed their role in the damaged kidney, 
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neutrophils undergo apoptotic cell death. The phagocytic uptake of apoptotic neutrophils 
(and other cells) and other anti-inflammatory signals favor macrophage polarization toward 
anti-inflammatory (M2c) or profibrotic (M2a) M2 phenotypes (Swaminathan & Griffin, 
2008). Furthermore, tumor-conditioned granulocytes may play a role in priming 
macrophages toward either an M1 or M2 phenotype (Tsuda et al., 2004). 
2.2 Monocytes and macrophages  
Cells of monocyte/macrophage lineage are always present and are the predominant 
infiltrating cell type both in experimental models and in human chronic kidney diseases 
(CKDs). Macrophages produce a wide variety of different cytokines, chemokines and 
growth factors, reactive oxygen and nitrogen species, matrix metalloproteinases and 
component of the extracellular matrix. Thus, the presence of macrophages often correlates 
with the degree of fibrosis, so infiltrated macrophages has been considered to be key effector 
cells by modulating inflammatory response and subsequent proliferation of myofibroblasts, 
extracellular matrix deposition and other fibrotic processes (Eddy, 1995). However, a 
significant number of reports noted an inverse correlation between the number of interstitial 
macrophages and the degree of fibrosis, especially at the later stage of the CKD. Therefore 
macrophages are also assumed to have a role in the repair processes of the injured kidney 
(Kushiyama et al., 2010; Cochrane et al., 2005). How is it possible that macrophages have 
functions, which are so different from each other? Recent works indicates that recruited 
monocytes may differentiate into at least two different types of tissue macrophages (Anders 
& Riu, 2011). Renal infection (bacterial or fungal cell wall components, viruses), degraded 
ECM or cell necrosis induces the differentiation of proinflammatory, “classically activated” 
M1 macrophages that may exacerbate renal cell damage. In contrast, uptake of apoptotic 
cells induces “alternatively activated” M2 macrophages, which have anti-inflammatory 
(M2c/suppressor), profibrotic (M2a/wound healing) or fibrolytic (M2b) properties (Gordon 
& Taylor, 2005; Mosser & Edwards, 2008; Mantovani et al., 2004). In renal fibrosis, classically 
and alternatively activated macrophage functions are not always sharply separated from 
each other, since some factors are required in the development and functions of both types. 
2.2.1 Classically activated ‘M1’ macrophages 
Tissue injury triggers a rapid influx of neutrophils that is followed by an increased adhesion 
of circulating monocytes to the activated endothelial surfaces and their subsequent 
extravasation into the renal interstitium (Muller, 2009). In obstructive nephropathy, flow 
cytometric analysis revealed a marked increase in cell counts of macrophages in the 
obstructed kidney. The depletion of Mac-1/CD11b+ monocyte lineages including 
macrophages and dendritic cells attenuated renal fibrosis, thus suggesting the importance of 
monocyte lineage in the development of the early phase of renal fibrotic diseases (Machida 
et al., 2010). Duffield et al. also showed that macrophage depletion reduced the number of 
interstitial myofibroblasts and CD4+ T lymhocytes, and attenuated the degree of fibrosis in 
the diseased kidney (Duffield et al., 2005). Renal epithelial, capillary endothelial cells and 
infiltrated leukocytes produce various chemokines, which are responsible for the early 
recruitment of macrophages into the injured tissue (Crisman et al., 2001). For example the 
levels of CC chemokines (MCP-1/CCL-2, macrophage inhibitory protein (MIP)-1α/CCL-3, 
“regulated on activation normal T cell expressed and secreted” (RANTES/CCL-5)) are 
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quickly increased after unilateral ureteral obstruction (UUO) (Vielhauer et al., 2001). 
Targeted deletion or blockade of these chemokines (Wada et al., 2004; Li et al., 2005) or 
chemokine receptors (Kitagawa et al., 2004; Eis et al., 2004) primarily interrupted the initial 
phase of macrophage infiltration and resulted in reduced inflammation and subsequent 
renal fibrosis. Also at the early stage of inflammation, DAMP (such as ATP, uric acid, 
hypomethylated DNA) or PAMP (such as bacterial lipopolysaccharide), lipoteichoic acid, 
peptidoglycan, double-stranded RNA, unmethylated CpG motifs) activate Toll-like (TLR) 
and other pattern recognition receptors of leukocytes and inherent renal cells. TLR 
activation on the monocytes and the presence of interferon (IFN)-γ are essential for the 
expression of interferon-related factor 5. It is required for the complete activation of NF-κB 
signaling and thus for the maturation of the proinflammatory M1 macrophage phenotype 
(Krausgruber et al., 2011). However, after the early inflammation response, in the 
progressive fibrotic stage macrophage activation may occur in TLR-independent pathways 
as well (Chowdhury et al., 2010). In addition, in the most types of glomerulonephritis, 
immune complexes can deposit in the glomerulus and bind leukocyte receptors including 
activating immunoglobulin Fc receptors and complement receptors to activate macrophages 
with similar activation and cytokine release pattern that described for DAMP/PAMP 
signals (Ravetch et al., 2001). The mature proinflammatory M1 macrophages then release 
matrix-metalloproteases (MMPs), which may induce the destruction of vascular and tubular 
basement membranes and further migration of inflammatory and fibrotic cells into the 
interstitial space (Song et al., 2000; Gibbs et al., 1999). MMPs also promote the degradation 
of ECM that results small ECM fragments, which can serve as immunstimulatory DAMP 
signals to maintain M1 macrophage phenotype (Sorokin, 2004). Stimulation of the 
production of MMPs by M1 macrophages during the later stages of fibrosis may shift the 
equilibrium towards ECM degradation and play an important anti-fibrotic role (see below). 
In M1 macrophages NF-κB is activated early after renal damage and controls the expression 
of multiple proinflammatory factors, such as chemokines (to recruit additional immune 
cells), adhesion molecules (to help the leukocyte adhesion and extravasation into the tissue), 
proinflammatory cytokines (to activate tissue or accumulated immune cells), lipid mediators 
and reactive oxygen species that support neutrophils in direct pathogen killing (Blackwell & 
Christman 1997). Furthermore, in M1 macrophages the synthesis of inducible nitric oxide 
synthase is also triggered by NF-κB proinflammatory pathway (Musial & Eissa, 2001). Nitric 
oxide (NO) produced by inducible nitric oxide synthase has a well known protective 
function against renal fibrosis (Hochberg et al., 2000; Morrissey et al., 1996). M1 
macrophages express Major Histocompatibility Complex (MHC) class II molecules on their 
cell surface, so have antigen-presenting capacity to activate naive T cells by antigen-specific 
manner. In this process macrophage IL-12 and IL-18 as a cofactor play an important role, 
because they promote the generation of T helper (Th)1 cell phenotype and potentially 
maintenance of proinflammatory Th1 responses (Kitching et al., 2005). M1 macrophages 
produce one of the most important proinflammatory cytokine IL-6, which have a significant 
role in releasing acute phase proteins from the liver, which is an early sign of inflammation. 
Elevated levels of the acute phase C-reactive protein may promote early renal inflammation 
and fibrosis by the activation of both proinflammatory NF-κB and profibrotic transforming 
growth factor (TGF)-ǃ/Smad signaling pathways (Li et al., 2011). Following renal damage, 
renal epithelial cells, denditic cells and M1 macrophages release large amount of TNF-α, 
which has a paracrine/autocrine effect on macrophage activation. TNF-α mediates 
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proapoptotic effects to limit the survival of activated immune cells (Wajant et al., 2003), but 
also induces activation and apoptosis of renal mesangial cells (Misseri et al., 2005; Duffield 
et al., 2000). NF-κB regulates the expression of TNF-α, which in turn may activate NF-κB 
(Ozes et al., 1999). Like TNF-α, after renal injury IL-1 cytokine levels are also upregulated. 
IL-1 may contribute to the development of renal interstitial injury and fibrosis, because IL-1 
receptor blockade decreases the number of infiltrated macrophages and alpha smooth 
muscle actin (α-SMA)+ myofibroblasts (Yamagishi et al., 2001).  
2.2.2 Alternatively activated ‘M2’ macrophages 
Apoptotic cells of the injured kidney are rapidly recognized and phagocytosed by 
macrophages. This process effectively promotes their differentiation into alternatively 
activated M2 macrophages (Ricardo et al., 2008; Fadok et al., 1998). M2 macrophages express 
typically high-level of scavenger and mannose receptors, which may promote macrophage 
activation and phagocytosis by a TLR-independent manner. Besides the phagocytosis of 
apoptotic cells, the induction of M2 macrophages requires other anti-inflammatory signals 
favor macrophage polarization, like Th2 or regulatory T (Treg) cytokines and other anti-
inflammatory agents such as corticosteroids (Goerdt & Orfanos, 1999). Like M1 
macrophages, M2 macrophages are also characterized by expression of MHC class II 
molecules, and have antigen-presenting capacity to activate naive T cells towards Th2 or 
Treg phenotype (Gordon, 2003). The phagocytosis of the apoptotic cells that generated 
during the early immune response especially promotes the differentiation of anti-
inflammatory M2c/supressor phenotype (Swaminathan & Griffin, 2008). Regulatory T cells 
via release of IL-10 and TGF-β are also required to the polarization of macrophages towards 
type M2c. M2c macrophages attenuate organ injury by downregulating inflammation, 
predominantly the Th1 response (Herbert et al., 2004). They secrete anti-inflammatory 
mediators, such as IL-10, TGF-β and other immune suppressive factors (Mosser & Edwards, 
2008). Furthermore, M2c macrophages play a positive role in epithelial (tubular 
reepithelization) and vascular (angiogenesis) repair and tissue remodeling. Insufficient 
tissue repair lead to increased secretion of different profibrotic cytokines and growth factors 
such as TGF-β (Kaneto et al., 1993) or platelet derived growth factor receptor (PDGF) 
(Fellström et al., 1989), which promote the differentiation of macrophages into M2a/wound 
healing macrophages that accelerate fibrogenesis (Gurtner et al., 2008). This process is 
supported by Th2 cells that release IL-4 and IL-13 cytokines, which further promote the 
polarization of M2a macrophage phenotype (Mantovani et al., 2004). M2a macrophages 
preferentially express the macrophage scavenger receptor (CD204), the mannose receptor 
(CD206) and fibronectin-1 which provide signals for tissue repair and proliferation. M2a 
macrophages are characterized  by the generation of arginase-1, which may enhance 
collagen biosynthesis by supressing proinflammatory NO production (Bronte & Zanovello, 
2005). Interestingly organ fibrosis may be reversible. Recently the role of fibrolytic M2b 
macrophages was demonstrated in this process. Actually M2b macrophages have the 
potential to limit or reverse fibrogenesis by the secretion of different matrix 
metalloproteinases (Ronco & Chatziantoniou, 2008). MMPs have a digestive capacity against 
ECM proteins (especially against collagen IV and denatured collagen I) without concomitant 
secretion of proinflammatory cytokines. Indeed MMPs have dual role in renal inflammation 
and fibrosis (Zeisberg et al., 2006). During UUO the expression of tissue inhibitor of 
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metalloproteinases-1 (TIMP-1) and -2 (TIMP-2), which are the main regulators of MMP 
synthesis can vary. Increased TIMP activity during the early phase of renal fibrosis lead to 
the decreased expression of MMP-2 and MMP-9 in the obstructed kidneys, which inhibits 
the degradation of ECM components. However, TIMP expression is attenuated in the 
chronic stage of UUO, which allows MMP synthesis by fibrolytic macrophages and ECM 
degradation, so collagen levels may return to control values (Sharma et al., 1995; Kim et al., 
2001). Recent studies demonstrated that the early inhibition of MMP-2 activity ameliorates 
renal fibrosis, but MMP-2 inhibition during the late phase of fibrosis may results in more 
severe disease progression (Nishida et al., 2007; Lutz et al., 2005).  
2.3 Dendritic cells 
Dendritic cells (DCs) are antigen-presenting innate immune cells, which belong to the 
mononuclear phagocyte system and fulfill a sentinel function. In the obstructed kidney, flow 
cytometric analysis showed– beside other leukocytes - increased number of F4/80+ 
macrophages and dendritic cells (Machida et al., 2010). Kitamoto et al. demonstrated in the 
early stage of UUO, that either F4/80+ monocytes/macrophages, F4/80+ dendritic cells, or 
both cell types contribute to the development of renal fibrosis and tubular apoptosis 
(Kitamoto et al., 2009). Other studies found that DC accumulation in the interstitium is 
associated with the loss of renal function and the progression of tubulointerstitial fibrosis 
(Wu et al., 2006; Zhou et al., 2009). According to their typical antigen and chemokine 
expression and the tendency to migrate toward inflamed tissue DCs are differentiated either 
myeloid (mDC) or plasmacytoid phenotype (pDC). Myeloid DCs are characterized by the 
expression of CD11c/blood dendritic cell antigen 1, while the specific marker of 
plasmacytoid DCs is the CD11c/ blood dendritic cell antigen 2. Verkade et al. showed an 
impaired terminal differentiation of mDCs in patients with severe chronic kidney disease 
(Verkade et al., 2007). Tucci et al found that the number of peripheral pDCs is correlated 
with the degree of lupus nephritis, whereas mDCs were almost absent in the glomeruli. In 
this disease only IL-18R+ pDCs were susceptible to increased expression of IL-18 and 
relocate within the glomeruli, where they triggers the resident T cells, thus promoting renal 
damage (Tucci et al., 2008, 2009). Infiltrated DCs become activated through pattern 
recognition receptors by DAMP/PAMP signals or by immune complexes via Fc receptors or 
complement receptors. These dendritic cells are the early source of the proinflammatory 
mediators after acute kidney injury and play a specific role in recruitment and activation of 
effector/memory T cells. The capacity of macrophages and dendritic cells to present 
antigens on MHC molecules and additionally produce IL-12/IL-23 or IL-10 strongly 
influences the outcome of the Th1/Th17 or Th2 T cell response (Langenkamp et al., 2000; 
Dong et al., 2008; Liu et al, 1998). Dendritic cell-specific intercellular adhesion molecule 3-
grabbing nonintegrin (DC-SIGN) is a marker of dendritic cells, which is important for DC in 
migrating, recognizing, antigen presenting and in initiating T cell responses. In a nephritis 
model, the expression of DC-SIGN, which was mainly expressed on tubular epithelial cells 
and DCs correlated with the degree of fibrosis, and was elevated by TNF-α treatment. These 
results suggest that DC-SIGN plays an important role in renal fibrosis by DC-mediated 
immuno-inflammatory responses (Zhou et al., 2009). Angiotensin II (Ang II) mediates 
proinflammatory effect also in the relationship of DCs, because AngII blockade with the 
Ang II receptor antagonist valsartan inhibited the local accumulation of dendritic cells and 
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attenuated renal tubulointerstitial damage in rat fibrotic renal tissue (Wu et al, 2006). Muller 
et al demonstrated by using human renin and angiotensinogen double-transgenic rats, that 
Ang II induces DC migration directly, whereas in vivo TNF-α is involved in DC infiltration 
and maturation (Muller et al., 2002). 
2.4 Mast cells 
Mast cells (MCs) are known to participate in the pathogenesis of tubulointerstitial fibrosis in 
the different kidney diseases (Colvin et al., 1974; Pavone-Macaluso, 1960). MCs are present 
in every vascularized tissue, including the kidney (Kitamura, 1989). The localization of MCs 
is mainly interstitial, or in smaller extent periglomerular, but they have were never found in 
the glomeruli (Ehara & Shigematsu, 1998;  Hiromura et al., 1998). MCs can be identified by 
their specific granular proteoglycans content by staining with metachromatic dyes or by 
using immunohistochemical staining with anti-tryptase and anti-chymase antibodies. In 
general, three MC subtypes are present in the kidney: the tryptase-positive mucosal type, 
the double-positive tryptase–chymase connective tissue type, and the third chymase-
positive type MCs. The ratio of the different subtypes of MCs (in the renal interstitium can 
differ in the various renal diseases (Beil et al., 1998). There are certain factors, which can 
promote the recruitment of MCs into the damaged kidney. Perhaps the most well known is 
the stem cell factor, which is known as the prototypic growth factor for MCs. Stem cell factor 
is produced mainly by tubular epithelial cells and by infiltrating interstitial leukocytes (El-
Koraie et al., 2001). TGF-ǃ also has been described as a powerful chemoattractant for MCs 
(Gruber et al., 1994). In addition to these factors, IL-9, a Th2 cytokine, may enhance survival 
and proliferation of MCs (Godfraind et al., 1998). The activation of mast cells takes place by 
different ways: while the classical pathway of mast cell activation is through 
Immunglobulin (Ig)E-Fcε receptor crosslinking (Beaven & Metzger, 1993), the alternative 
way includes the activation of pattern recognition (such as TLRs) (McCurdy et al., 2001; 
Supajatura et al., 2002) or complement receptors (Prodeus et al., 1997). Activated MCs have 
a capacity to secrete a large variety of inflammatory mediators such as a range of bioactive 
amines and proteoglycans; histamine, which is a potent vasodilator and enhance vascular 
permeability; lipid mediators such as prostaglandins and leukotrienes, which are potent 
chemoattractants for CD8+ T cells and a large set of chemokines and cytokines, which are 
able to recruiting and activating leukocytes (Galli et al., 2005). Furthermore, they promote 
the vascular endothelial expression of selectins and adhesion molecules, which indirectly 
support leukocyte recruitment (Meng et al., 1995). MCs also have a direct 
immunoregulatory role by interacting with T cells, B cells, and dendritic cells (Galli et al., 
2005). They are able to present antigens to naive T cells in an MHC-restricted manner 
(Dimitriadou et al., 1998) and influence T cell differentiation towards Th2 (by IL-4, IL-10 and 
histamin) (Jutel et al., 2002) or Th17 phenotype (Nakae et al., 2007). Furthermore, MCs seem 
to be essential to induce the development of Tregs that limit the infiltration of autoreactive T 
cells, and mediate peripheral tolerance (Lu et al., 2006). Experimental studies suggest that 
degranulation of MCs leads to the release of TGF-ǃ, TNF-ǂ, MCP-1, fibroblast growth factor 
(FGF), vascular endothelial growth factor (VEGF), IL-4 and MMP-9 and a variety of unique 
proteases, principally tryptase and chymase (Holdsworth & Summers, 2008), which 
contribute to progressive fibrogenesis (Cairns & Walls, 1997). Tryptase is prestored in 
cytoplasmic granules of MCs and has potent proteolytic activity against ECM proteins 
(Payne & Kam, 2004) and it supports the proliferation of fibroblasts and the synthesis of 
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type I collagen (Cairns & Walls, 1997). Chymase can activate MMP-2 and MMP-9, disrupt of 
tight junction proteins (Scudamore et al., 1998) and involved in the activation of renin–
angiotensin system (Huang et al., 2003). On the other hand MCs can also participate in 
tissue remodeling and restoration of the normal kidney homeostasis (Bradding et al., 2006; 
Bankl & Valent, 2002). For example heparin produced by MCs is a potent anti-thrombotic, 
anti-inflammatory, anti-coagulant and anti-fibrotic agent, which is able to modulate renal 
fibroblast proliferation by arachidonic acid-derived lipid mediators such as leukotriene and 
prostaglandin (Clarkson et al., 1998) or by inhibition of TGF-ǃ (Miyazawa et al., 2004). 
2.5 T lymphocytes 
T lymphocytes are main effector cells of adaptive immune system and activated by specific 
antigen stimuli. Although macrophages constitute the predominant infiltrating cell 
population of the injured kidneys, increased number of T lymphocytes were also observed 
in chronic renal diseases. It is also well known that the degree of tubulointerstitial fibrosis is 
related to the number of infiltrating T cell, implying their role in the fibrotic process 
(Tapmeier et al., 2010). In accordance with this observation Niedermayer et al. have shown 
that lymphocyte deficiency cause a substantial reduction in collagen I deposition in the 
obstructed kidney (Niedermayer et al., 2009). In the early phase of renal injury 
chemoattractants released by damaged and infiltrating immune cells directing the migration 
of activated T lymphocytes into the injured tissue. In this process CC (RANTES/CCL5), 
CXC (IP-10/CXCL10) chemokines, MIPs, lipid mediators (leukotriene) and anaphylatoxic 
complement fragments play a pivotal role (Kuroiwa et al., 2000). The activation of T cells 
occurs by antigenspecific manner. Antigens are presented by MHC molecules expressed on 
the cell surface of antigen-presenting cells (dendritic cells, macrophages, B cells) and 
recognized by T cell receptor/CD3 complex, which are the specific antigen-recognizing 
receptors of T lymphocytes. There are two different populations of the effector T 
lymphocytes: while CD8+ cytotoxic T cells have a direct cell-killing activity, Th cells are 
characterized by the expression of CD4 costimulator molecule and release a wide range of 
cytokines to mediate immune functions. Endogen antigens are presented on MHC type I 
molecules to CD8+ T cells, while exogen antigens are presented on MHC type II molecules 
to CD4+ T cells. After antigen recognition T cells become activated effector T cells or long-
lived memory T cells. Cytokines released by the antigen presenting cells, such as 
macrophages and dendritic cells play a pivotal role in polarization of CD4+ T cells to 
different Th subtypes: IL-12 and IL-18 as a cofactor promote the generation of Th1 
phenotype and the proinflammatory Th1-type cellular immune response. In Goldblatt 
hypertensive rats antihypertensive therapy induces a significant proinflammatory Th1 
immune response with increased Th1-type chemokine (IP-10) and cytokine (IFN-Ǆ) 
expression (Steinmetz et al., 2007). Similarly, the absence of Ang II type 1 receptor (AT1) in 
AT1R KO mice is associated with Th1-type immune response (Ouyang et al., 2005). IFN-γ, 
which is secreted by Th1 cells (and also other immune cells) is required to the classical 
activation of M1-type macrophages, which have proinflammatory but not fibrotic 
properties. These data suggest that Th1 cells mediate proinflammatory, rather than fibrotic 
effects. Th2 lymphocytes may mediate the activation of alternatively activated M2 type 
macrophages by producing IL-4, IL-5, IL-10, IL-13 and TGF-β. The activated M2 
macrophages may promote fibrotic diseases and mediate collagen synthesis, suggesting the 
role of Th2-mediated immune response in fibrotic process (Wynn, 2004). Beside Th1-Th2 
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polarization, the Treg-Th17 axis is the other important player of immune response observed 
in chronic kidney diseases. Foxp3+ Treg have immunoregulatory and anti-inflammatory 
role via release of TGF-β and IL-10 (Mu et al., 2005). IL-10-secreting Treg cells suppress the 
activation of Th1, Th2 and Th17 cells, thus ameliorate the severity of inflammatory process, 
for example in mice with lupus nephritis (Zhang et al., 2010). Treg cells may promote the 
polarization of monocytes towards M2 macrophages, which may mediate profibrotic effects. 
Th17 cells produce IL-17 (IL-17A), IL-17F, IL-21, IL-22 which may promote inflammation by 
directly causing tissue injury and enhancing secretion of proinflammatory cytokines and 
chemokines by resident cells. This results in augmented infiltration of leukocytes, mainly 
neutrophils to the injured tissue where they induce inflammation (Turner et al., 2010). 
Dudas et al. described that IL-17A also mediate proinflammatory/profibrotic activity on 
proximal tubule epithelial cells that may contribute to allograft rejection (Dudas et al., 2011). 
In general both CD8 and CD4 positive cells may directly stimulate the migration, 
proliferation and differentiation of renal cells resulting in the accumulation of ǂ-SMA 
positive myofibroblasts. T cells may also act indirectly on the infiltrating macrophage 
population by inducing a profibrotic phenotype, which, in turn, secrete pro-proliferative 
and profibrotic cytokines and growth factors (for example PDGF, TGF-ǃ). Moreover, T cells 
may directly interact with epithelial cells to induce secretion of cytokines and growth factors 
that, in turn, act on fibroblasts (Strutz & Neilson, 1994).  
2.6 B lymphocytes  
B lymphocytes are effector cells of the adaptive immune system. B cells are activated 
through their specific antigen-recognizing B cell receptor complex on T cell dependent or 
independent manner. Activated B cells mature to plasma cells and mediate humoral 
immune response by producing specific antibodies or differentiate into long-lived memory 
B cells. B cells themselves may also act as antigen presenting cells and influence T cell 
response in the lymphoid folliculi.  B cells may contribute to renal fibrosis in different ways, 
but their exact role in the process is less known. On the one hand autoantibodies produced 
by B cells are largely present in immune complexes, which may accumulate in the glomeruli 
in severe autoimmune and kidney diseases and activate innate immune cells by their 
immunoglobulin Fc receptors. Autoantibody synthesis could also occur after bacterial or 
viral infection, oxidant synthesis, or T cell mediated immunity.  
On the other hand infiltrated B cells have an important role in renal interstitial 
inflammation: indeed, Heller et al. found that mature B cells formed a prominent part of the 
renal interstitial infiltrating cells in renal biopsies from patients with acute or chronic 
interstitial nephritis and IgA nephropathy. The expression of CXCL13, which is a 
chemoattractant for B cells, was elevated in these inflamed kidneys. CXCL13 level was 
correlated with the infiltrated B cell number and contributed to the formation of intrarenal 
lymphoid follicle-like structures, which might represent an intrarenal immune system 
(Heller et al., 2007). B cell activating factor – which belongs to TNF superfamily - has an 
important role in the development and survival of B lymphocytes. Xu et al. demonstrated in 
kidney allograft biopsies, that B cell activating factor expression may be associated with the 
development of antibody-mediated allograft rejection and renal interstitial fibrosis in kidney 
transplants (Xu et al., 2009). Moreover, IgG4-associated tubulointerstitial nephritis is 
characterized by high levels of serum IgG4 and IgE and a significant number of IgG4-
producing plasma cells in the renal fibrotic lesions (Saeki et al., 2007; Raissian et al., 2011). 
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2.7 Complement activation  
Complement system is an essential, and conserved part of the immune system, defends the 
host against invading pathogens, prevents immune complex disease and aids the acquired 
immune response. It consists of a number of small proteins, which are generally synthesized 
by the liver and normally circulating in the blood as inactive precursors. In response to 
several triggers, proteases (convertases) cleave the specific proteins of the complement 
system and initiate a cascade of further cleavages. Finally the activated complement proteins 
as multimeric membrane attack complexes bind to the surface of target cells and and lyse 
them (Lesher & Song, 2010). Immune complexes contain a large amount of complement 
fragments, which may accumulate in the glomeruli in different autoimmune diseases and 
activate the innate immune cells by their complement receptors. Detection of complement 
deposition in the glomerulus using immunochemistry has become an important element of 
the histological analysis of renal biopsies, and is key to the diagnosis of many types of 
glomerulonephritis. In recent years it has become evident that complement activation is 
involved in the pathogenesis of other types of renal disease including progressive 
tubulointerstitial fibrosis (Brown et al., 2007). For example, deficiency in the expression of 
C5 (Boor et al., 2007), C4d (Xu et al., 2009) or C6 (He et al., 2005) complement fragments 
caused reduced renal damage and interstitial fibrosis in different kidney diseases. Blocking 
the receptors of the potent anaphylatoxins C5a and C3a lead to significantly reduced renal 
leukocyte infiltration, tubulointerstitial inflammation and fibrosis (Boor et al., 2007; Bao et 
al., 2011).  
3. Important molecular pathways 
In addition to the above mentioned activation of the immune cells the increased amount of 
different cytokines and growth factors are also participate in the accumulation of the ECM 
in renal the interstitium along the tubules. To date more than a dozen different cytokines 
(IFNǄ, IL-1), growth factors (TGF, connective tissue growth factor, bone morphogenic 
protein, Insulin-like growth factor-1, TNFǂ) and other molecules (Ang II, NO) have been 
demonstrated to induce interstitial inflammation, maturation of myofibroblasts and 
degradation or production of ECM. Here we are going to summarize our knowledge about 
TGFǃ, Ang II and PDGF and their downstream signaling pathways. 
3.1 Transforming Growth Factor β (TGF β) 
TGFǃ is a member of the TGFǃ superfamily that include activins, inhibins and bone 
morfogenic proteins (Peng, 2003). In the healthy kidney TGFǃ participate in the maintaining 
of the homeostasis. However, when the kidney is exposed to an injury then TGFǃ is 
excessively produced by the resident renal cells and also by the infiltrating leukocytes 
(Border & Noble, 1993; Coimbra et al., 1996; Eddy, 2000). Fukuda et al. (Fukuda et al., 2001) 
using in situ hybridization and immunohistochemistry demonstrated that TGFǃ1 is mainly 
expressed by mesangial and epithelial cells of the glomeruli and the distal tubules in the 
healthy kidneys. Following UUO they observed increased TGFǃ1 expression in the renal 
tubular epithelial cells of the renal cortex and outer medulla and also in the infiltrating 
macrophages. Indeed similar upregulation of TGFǃ is present in every animal model of 
chronic renal disease and also in humans (Ketteler et al., 1994). 
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TGFǃ1 and its isoforms (TGFǃ2 and 3) are secreted as precursos in a complex with latent 
TGFǃ binding proteins. TGFǃ become active when it is cleaved by plasmin, 
thrombospondin-1 or reactive oxygen species and thus dissociated from latent TGFǃ 
binding proteins. The activated TGFǃ then form dimers and bind to their type I and II cell-
surface serin/threonine kinase receptors (TBR I and TBR II, respectively). So far two TBR I 
(activin like receptor kinase 1 and 5) and one TBR II (TGFBR2) have been have been shown 
to bind TGFǃ. TGFǃ first binds to the constitutively active TBR II followed by the 
phosphorylation of the glycine/serin rich domain of the TBR I to create activated receptor 
heterodimer. Subsequently the activated receptor complex phosphorilates the downstream 
signaling mediators such as SMAD2/3, ERK1/2, Jun N-terminal Kinase 1/2 (Matsuzaki & 
Okazaki, 2006). In the injured tissue TGFǃ through its activated signaling pathways can 
trigger the increased production and decreased degradation of ECM (Pohlers et al., 2009) 
and thus the renal fibrosis. Koesters et al. showed marked peritubular fibrosis in the double 
transgenic mice overexpressing TGFǃ1 in their tubular epithelial cells (Koesters et al., 2010). 
They observed the proliferation of the peritubular cells and the deposition of collagen type I 
rich ECM. Moreover, they observed the TGFǃ1 dependent autophagy of the tubular cells 
which may represent a novel mechanism of tubular decomposition. On the other hand Isaka 
et al. demonstrated that introduction of antisense oligodeoxynucleotides against TGFǃ1 into 
interstitial fibroblasts block the interstitial fibrosis in rats with unilateral ureteral obstruction 
(Isaka et al., 2000). Similarly, Miyajima et al. observed that administration of neutralizing 
anti-TGFǃ1 antibody attenuate the tubular apoptosis in a rat model of UUO (Miyajima et al., 
2000). Also Decorin, which is an ECM protein that bind TGFǃ, or soluble TGFǃ receptor 
have been also shown to inhibit renal fibrosis (Peters et al., 1997; De Heer et al., 2000). 
3.2 Renin-Angiotensin System  
The RAS is the most important regulator of blood pressure, fluid and electrolyte 
homeostasis. The different components of the Renin-Angiotensin System, such as 
angiotensinogen, renin, AngI, angiotensin converting enzyme (ACE) Ang II, aldosterone 
and Ang II type I and II (AT1, AT2, respectively) receptors are all present in the kidney. 
Renin acts on angiotensinogen to form AngI, which is then converted by ACE to Ang II. The 
effects of Ang II are mediated by two high affinity receptors, AT1 and AT2. Since the overall 
abundance of AT1 receptors significantly exceeds that of AT2 type receptors in the adult 
kidney the most effects of Ang II are mediated through the AT1 receptor (Siragy, 2004). AT1 
receptors are distributed on the luminal surface of the renal tubules, including proximal 
tubule, thick ascending limb of loop of Henle, distal tubule, macula densa and collecting 
duct (Allen et al., 2000). Recently the urinary angiotensinogen (Kim et al., 2011) and the 
intrarenal Ang II level (Del Prete et al., 2003) have been demonstrated to correlate with the 
severity of the chronic renal disease. As Ang II plays a key role in regulation of vascular 
tone (Cockcroft et al., 1995) and may induce proteinuria (Ren et al., 2011), oxidative stress, 
inflammation and renal fibrosis (Benigni et al., 2010) it is not surprising that ACE inhibitors 
or AT1 receptor antagonists have a renoprotective effect, which is independent from their 
antihypertensive effect (Mallamaci et al., 2011). Actually, the captopril trial on patients with 
type I diabetic nephropathy patients has shown a 50 % reduction in the end point of death 
by captopril administration (Lewis et al, 2003). Although the clinical relevance of Ang II in 
chronic renal disease is obvious, its precise role is still unclear. It is well known that Ang II 
may induce EMT on the epithelial cells in vitro. However, since the significance of in vivo 
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EMT is strongly questioned the in vivo relevance of Ang II on EMT is also questionable. 
Recently Kang et al. revealed that Ang II may decrease the NF-E2-related factor 2 (Nrf2) 
mediated signaling in murine renal epithelial TCMK-1 cells (Kang et al., 2011). Nrf2 is a 
transcriptional factor which by binding to the antioxidant response element on the promoter 
of different antioxidant genes can induce their expression. Kang et al. suggested that Ang II 
by inducing activating transcription factor 3 expression could inhibit the Nrf2 mediated 
upregulation of the antioxidant genes. Ang II increases vascular permeability via the release 
of prostaglandins and VEGF; contribute to the recruitment of inflammatory cells into the 
tissue through the regulation of adhesion molecules, chemokines (MCP-1, RANTES) and 
other molecules (osteopontin, see above) by resident cells; could directly activate infiltrating 
immunocompetent cells by cytokines (such as IL-6). AT1R or AT2R blockade (Esteban et al., 
2003; Kellner et al., 2006) or treatment with ACE inhibitors (Ishidoya et al., 1995) greatly 
reduced monocyte/macrophage infiltration in short-term UUO, and AT1R-deficient 
macrophages have impaired phagocytic function (Nishida et al., 2002). Finally Ang II also 
may increase the expression of other molecules that play a pivotal role in organ fibrosis 
inducing TGFǃ, TNFǂ or PDGF or bFGF (Rüster & Wolf, 2011). Moreover Ang II can 
potentiate the effect of TGFǃ on the expression of SMA in TCMK-1 cells. Furthermore, AngII 
participates in tissue repair and remodeling, through the regulation of cell growth and 
matrix synthesis (Suzuki et al., 2003). 
3.3 Platelet Derived Growth Factor (PDGF) 
PDGF is a growth factor that regulates multiple cell function, such as cell growth (Bonner, 
2004) or division and in particular in formation of blood vessels (Hellberg et al., 2010). 
Recently, its role in organ fibrosis has been also suggested (Trojanowska, 2008). PDGF 
family consist of five homo- or heterodimeric growth factors (PDGF-AA, -AB, -BB, -CC and -
DD).   PDGF-A has two splice variant, a longer (≈16 kD) which is retained to the cell surface 
and a shorter, which is released into the extracellular space. PDGF-AA and -BB can bind to 
different ECM proteins. PDGF-CC and -DD were identified just recently. PDGF-CC and -DD 
are secreted in a latent form and cleavage of the N terminal CUB (complement 
subcomponent C1r/C1s, Uegf and Bmp1) domain is required for their activation. While 
PDGF-CC is activated by tissue type plasminogen activator and plasmin PDGF-DD is 
activated by urokinase type plasminogen activator. Many inherent renal cell express one or 
more PDGF isoforms, such as pericytes (Winkler et al., 2010), podocytes (Changsirikulchai et 
al., 2002), endothelial (Eitner  et al., 2003), tubular epithelial (Eitner et al., 2002) and smooth 
muscle cells (Seifert et al., 1998). The different isoforms of PDGF bind to the homo- or 
heterodimeric tyrosine kinase receptors (PDGFR-ǂǂ, -ǃǃ and -ǂǃ). The specifity and affinity 
of the different PDGF monomers to the ǂ or ǃ chain of the receptor PDGFRs are different. 
While PDGF-A can bind to the ǂ, PDGF-B to the ǂ and ǃ chains. The receptor affinity of 
PDGF-C and –D is less characterized, but it is likely that similarly to PDGF-B they can bind 
to the ǂ and ǃ chain as well. Upon receptor binding the ǂ and ǃ chains dimerize and 
possesses tyrosine kinase activity. After autophosphorylation the PDGFRs provide docking 
site for downstream signaling molecules containing SH2 (Floege J, 2008), SH3, PTB, PH 
(Andrae et al., 2008) and other domains thus activating several signaling pathways such as 
MAPK, PLCǄ or PI3K (Ostendorf et al., 2011). Increased expression of the different PDGF 
isoforms was observed in most if not all animal models of kidney injury. PDGFR-ǂ chain, 
which is the receptor for PDGF-A and -C is widely expressed in the different renal cell 
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types, such as myofibroblasts, mesangial and smooth muscle cells (Alpers et al., 1993). 
Interestingly, while infusion of high doses of PDGF-A (5mg/kg) did not induced renal 
lesion (Tang et al., 1996) inhibition of PDGF-C with a neutralizing antibody exhibited a 
significant reduction of renal fibrosis, myofibroblast accumulation and decreased leukocyte 
infiltration in a mice model of UUO (Eitner et al., 2008).  PDGF-BB has a central proliferative 
effect on the mesangial cells. Actually infusion of PDGF-BB into of healthy rats led to 
increased mesangial cell proliferation and accumulation of the mesangial matrix (Tang et al., 
1996). More recently, the role of PDGF has been suggested in the transformation of 
pericytes, the main source of myofibroblasts, into myofibroblasts following kidney injury 
(Chen et al., 2011). Inhibition of PDGFR-ǂ or PDGFR-ǃ signaling with a neutralizing 
antibody or with Imatinib, a PDGF tyrosine kinase inhibitor, treatment the UUO induced 
differentiation and proliferation of the pericytes decreased. The treatment of the animals 
with a neutralizing antibody against PDGFR-ǂ or PDGFR-ǃ reduced the UUO induced 
macrophage infiltration, renal TGFǃ, PDGF and CCL2 expression and renal fibrosis. Hence 
PDGFR-ǂ and PDGFR-ǃ are potential candidates for antifibrotic therapy in the future.  
4. Origin of myofibroblasts 
Understanding the origin of myofibroblasts in the kidney is great interest because these cells 
are responsible for scar formation in fibrotic kidney diseases. Myofibroblasts have migratory 
capacity, are resistant to apoptosis, and can produce different components of the 
extracellular matrix, growth factors, cytokines and therefore contribute to organ fibrosis and 
to the maintenance of inflammation (Zeisberg et al., 2008). Actually, in the healthy kidney 
there are no known endogenous myofibroblasts. In the fibrotic kidney (as in other organs) 
the origin of the renal myofibroblast is still controversial, however there are some 
hypotheses. Recently the derivation of myofibroblasts from epithelial or endothelial cells, 
fibrocytes and pericytes has been suggested (Fig. 1.).  
 
Fig. 1. Different possible origins of the myofibroblasts. There are different hypothesis about 
the possible origin of the myofibroblasts, which are effector cells of the organ fibrosis. The 
derivation of the myofibroblasts from endothelial and epithelial cells, from fibrocytes and 
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4.1 Epithelial-mesenchymal transition (EMT) 
A hypothesis that recently has become popular is the mesenchymal transition of the renal 
tubular epithelial cells. The process when the epithelial cells lose their polarity and epithelial 
adhesion properties and starts the de novo synthesis of mesenchymal markers, such as 
ǂSMA is the so called EMT. This process is already well known in different physiological 
and pathological processes, notably in embryogenesis, carcinogenesis (Kalluri & Weinberg, 
2009). The first remarkable evidence of EMT in the fibrotic kidney was demonstrated by Ng 
et al (Ng et al., 1998). They investigated the localization of ǂSMA after 1-21 weeks of 5/6 
nephrectomy of Sprague-Dawley rats. In normal kidneys in situ hybridization and 
immunohistochemical staining revealed the mRNA or protein expression of ǂSMA only in 
the vascular smooth muscle cells. Later on the 3rd week after the 5/6 nephrectomy, mRNA 
and protein expression of ǂSMA was present in the proximal tubular epithelial cells (TEC) 
as well. Indeed they observed a gradually increasing number of ǂSMA+ TEC peaking at 
week 9. Moreover, about 70% of the ǂSMA+ TEC were proliferating based on their 
proliferating cell nuclear antigen positivity. Finally these cells became elongated separated 
from their neighboring cells and appeared to migrate into the renal interstitium through the 
damaged basement membrane. These original observations were confirmed at the 
ultrasructural level of the renal tubules by electron microscopy. They found that in the early 
transformed TECs contain large round or oval shaped nucleus, several mitochondria 
indicating the activation of these cells. Characteristic microfilaments and dense bodies 
(stress fibers) were present in the transformed TECs, lying next to the damaged TBM. Later 
in advanced state of EMT TECs exhibit elongated morphology and abundant microfilaments 
and dense bodies. At this stage microfilaments are diffusely fill the entire cytoplasm of 
TECs. Later Iwano et al. strengthened the hypothesis of in vivo EMT using genetic fate 
mapping method (Iwano et al., 2002). Briefly, they developed transgen mice that express Cre 
recombinase under the promoter of ǄGT. As ǄGT is a brush border protein, its promoter is 
active only in the proximal TECs (PTEC). These ǄGT-Cre mice were then bred with a R26R 
reporter mice (Fig. 2). In the PTECs of the bigenic mice the expressed Cre recombinase 
mediates the excision of the loxP stop cassette and activate the expression of ǃ galactosidase 
from the gene of LacZ. Thus irreversibly marking the PTECs with ǃ galactosidase, despite 
the subsequent phenotypic changes. 
 
Fig. 2. Model of transgen mice that express Cre recombinase under the promoter of ǄGT. 
These ǄGT-Cre mice were then bred with a R26R reporter mice. 
Later, ten days after UUO the PTECs of the double transgenic, ǄGT-Cre; R26R mice started 
to express (beside ǃ galactosidase) fibroblast specific protein-1 (FSP-1), suggesting the EMT 
of TECs (Fig. 3/b; LacZ-red and FSP1-green, merge-yellow). Some of these FSP-1 and ǃ 
LoxP                LoxP
γGT promoter 
Cre
Rosa 26 promoter LacZSTOP
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galactosidase double positive PTECs also began to take an elongated shape of 
myofibroblasts (Fig. 3/b; arrows). Moreover, these double positive cells appeared in the 
fibrotic tissues surrounding the tubules (Fig. 3/c and d). Finally by counting the FSP1 and 
LacZ immunopositive cells in the renal interstitium, they suggested that after 10 days of 
UUO about 36% of the myofibroblasts originate from the renal tubular epithelial cells.  
 
Fig. 3. Confocal microscopy images of contralateral (a) and injured (b, c and d) kidneys 10 
days after the UUO (Iwano et al., 2002).  Proximal tubular epithelial cells are stained with an 
anti-ǃ galactosidase antibody (red) and the fibroblasts with an anti-FSP1 antibody (green). 
(b, c, d) Ten days after the onset of UUO the ǃ galactosidase positive PTECs also expressed 
FSP-1 (ǃ galactosidase+/FSP-1+ PTECs cells staining yellow), suggesting the mesenchymal 
transition of cells. (b, c, d) Some of these FSP-1+ PTECs (arrow) had the elongated shape of 
myofibroblasts, and appeared in the fibrotic tissues surrounding the tubules. (After Iwano et 
al., 2002) 
Subsequently numerous in vitro studies confirmed the original observation of Ng (Ng et al., 
1998) and Iwano et al. (Iwano  et al., 2002). These studies on different cell lines (HK-2, 
HEK298, NRK) and on primer renal tubular epithelial cells have clearly shown that 
epithelial cells when exposed to hypoxia, reactive oxygen species, advanced glycation end 
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products, pro-fibrotic cytokines, TGF-ǃ1, angiotensin II (ANGII), platelet-derived growth 
factor, epidermal growth factor and fibroblast growth factor-2 (Liu, 2010) growth factors or 
metalloproteinases (Yang & Liu, 2001) may undergo EMT. During EMT these molecules 
activate different signaling pathways on a coordinated manner. As a result the Ras/Rho 
GTPase, Rho-activated kinase, c-Src tyrozin kinase, Integrin-linked kinase, Wnt-1, Smad 2 
and 3, p38 mitogen-activated protein kinase, extracellular signal-regulated kinase (ERK) and 
phosphatidil-inositol-3 kinase (PI3K) signaling pathways can be activated (Thiery & 
Sleeman, 2006). Activation of these signaling pathways leads to the phenotypical conversion 
of the TECs. During EMT TECs lose their cellular polarity, downregulate epithelial markers 
and acquire mesenchymal features, such as the de novo synthesis of ǂ-SMA. Finally the 
epithelial cells are transformed to myofibroblasts as a determinative step in renal fibrosis 
(Iwano et al., 2002). In the 2008 EMT congress in Cold Spring Harbor according to the in 
vivo and in vitro findings this process that led to tissue scaring was defined as type II EMT. 
Based on these studies EMT has been widely accepted as one of the main mechanism by 
which myofibroblast formed during renal fibrosis. However the presence of this 
phenomenon, even on primer epithelial cells is evident in vitro, recently it has been 
questioned in vivo. Unfortunately, the results of Iwano et al. have not been confirmed by 
other groups. In contrast others using genetic fate mapping techniques were not able to 
demonstrate any evidence of EMT in vivo. Humphreys et al. developed two transgenic Cre 
driver mice that express bacterial Cre recombinase under the regulation of Six2 or HoxB7 
promoters (Humphreys et al., 2010) (Fig. 4/A). Both Six2 and HoxB7 are transcriptional 
factors that transiently expressed during development. Six2 is expressed only in those cells 
of metanephric mesenchyme that are fated to be epithelial cell of the proximal or distal 
tubules. HoxB7 is expressed in the cells of ureteric bund that are fated to be the cells of the 
collecting duct. These transgenic mice were bred with R26R reporter mice expressing ǃ 
galactosidase. In the kidney samples of the healthy Six2-Cre; R262 bigenic mice strong 
epithelial ǃ galactosidase activity was present in the podocytes and in the whole tubulus 
until the collecting duct. In case of HoxB7-Cre; R262 double transgenic mice this positivity 
was restricted to the epithelia of the collecting duct (Figure 4/B). Fourteen days after the 
UUO there was no change in the localization of ǃ galactosidase activity. ǃ galactosidase 
activity was present in the epithelial cell of the bigenic mice (Six2-Cre; R262 or HoxB7-Cre; 
R262), but none of the ǂSMA positive interstitial cells were positive for ǃ galactosidase 
activity. These results strongly suggest that epithelial cells do not leave their original place, 
behind the basement membrane and they do not migrate into the interstitium of the ureteral 
obstructed kidney. 
Based on these conflicting data it is not evident whether in vivo EMT is an existing process 
in the fibrotic kidney or not. While in vitro data strongly suggest the existence of EMT in 
vivo studies of Humphreys et al. and others suggest that TECs do not invade the basement 
membrane and do not become real interstitial myofibroblasts (Humphreys et al., 2010). But 
are the in vitro and in vivo data really contradictory? Actually in vitro studies investigate 
the molecular mechanism of EMT but do not investigate the basement membrane invading 
capacity of the transformed cells. On the other hand in vivo experiments investigate the 
basement membrane invading capacity of the TECs but do not investigate the molecular 
changes of the TECs during the fibrotic process. So some scientists believe that the aim of 
the in vitro and in vivo studies is different and thus the results of these studies are not 
necessarily contradictory. 
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Fig. 4. Control and kidneys 14 days after the UUO from Six2-GC; R26R and HoxB7-Cre; R26R 
mice show no evidence for ǃ galactosidase activity in the renal interstitium. A: Double 
transgen Six2-GC; R26R mice activated Cre expression in the cells of the metanephric 
mesenchyme that are fated to become the cells of the renal tubules. Expression of Cre results 
in removal of the LoxP-STOP-LoxP sequence in epithelial cells, leading to permanent, 
heritable expression of ǃ galactosidase in epithelial cells. Similarly in HoxB7-Cre; R26R mice 
activation of Cre expression in the ureteric bud led to the expression of ǃ galactosidase in 
the epithelial cells of the collecting duct. B: Representative light microscopy images of X-gal 
stain indicating of ǃ galactosidase activity in the control (left) and in the obstructed (right) 
kidneys. (After Humphreys et al., 2002) 
control            14 days after UUO 
Six2-Cre; R26R Six2-Cre; R26R 
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4.2 Endothelial-mesenchymal transition (EndMT)  
EndMT was first described during embryonic heart development, where mesenchymal cells 
of the endocardial cushion (a tissue that later gives rise to the cardiac septa and valves) arise 
from endothelial cells of the endocardium. Endothelium is a specialized type of a squamous 
type epithelium. Thus EndMT is a specific form of EMT. Simirarly to EMT during EndMT 
endothelial cells (EC) lose their endothelial markers and acquire markers of myofibroblasts. 
Studies on different organs have demonstrated the relevance of EndMT in the 
pathomechanism of organ fibrosis. Zeisberg et al. used Tie1 Cre; R26R bigenic mice to fate 
the EC during cardiac fibrosis (Zeisberg et al., 2007a). They have demonstrated that EC 
undergo phenotypic conversion and contribute to organ fibrosis. Similarly, Hashimoto et al. 
using Tie2 Cre; CAG-CAT-LacZ transgenic mice have shown that EC give a significant 
percent of myofibroblasts in bleomycin induced pulmonary fibrosis (Hashimoto et al., 2010). 
Recently, the importance of EndMT was suggested in different models of renal fibrosis as 
well. Zeisberg et al. investigated the contribution of endothelial cells to fibrosis in different 
animal models of CKD: 1) a mouse model of unilateral obstructive nephropathy; 2) a model 
of streptozotocin (STZ) induced DN; 3) a mouse model of Alport disease (COL4A3 KO, lack 
the collagen IV ǂ3 chain). First they investigated the effect of UUO on the population of FSP-
1 or ǂSMA positive myofibroblast. Previously, it has been demonstrated that FSP-1 or 
ǂSMA identify distinct population of myofibroblast with a minimal overlap between the 
different populations (Zeisberg et al., 2007a, 2007b). One week after the ligation of the ureter 
the number of the FSP-1 or ǂSMA positive myofibroblast population increased. To 
investigate the possible endothelial origin of the myofibroblast double immunostaining 
were performed. The number of the CD31 (marker of the EC) and FSP-1 or CD31 and ǂSMA 
positive myofibroblasts were 36% or 25%, respectively (Fig. 5).  
 
Fig. 5. Immune fluorescent staining to investigate the possible endothelial origin of the 
myofibroblast. CD31 (red) is a marker of ECs, FSP-1 (green) is that of myofibroblasts. (After 
work of Zeisberg et al., 2007). 
To strengthen the endothelial origin of these double CD31 and FSP-1 or CD31 and ǂSMA 
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cells of endothelial origin express yellow fluorescent protein (YFP). After UUO a substantial 
portion of FSP-1 or ǂSMA positive myofibroblast coexpressed YFP, suggesting their 
endothelial origin. These data strongly suggest that EndMT may account for a considerable 
percent of myofibroblasts in the mouse model of UUO. Zeisberg et al. also investigated the 
origin of myofibroblasts in a mouse STZ induced DN. They have demonstrated that 6 moths 
after the induction diabetes about 50% of the ǂSMA and 40% of the FSP-1 positive cells were 
also CD31 positive in the kidney, suggesting the relevance of EndMT in the fibrotic changes 
in DN. Finally, Zeisberg et al. investigated the origin of myofibroblast in COL4A3 KO mice, 
in a model of Alport syndrome. In these mice proteinuria, glomerulonephritis and 
tubulointersitial fibrosis starts at the 8th week of age. In the investigated 22 weeks old mice 
strong interstitial fibrosis was present as revealed by the Masson Trichrome staining (MTS). 
In accordance with MTS the number of myofibroblast was elevated in COL4A3 KO 
compared to wild type mice. To investigate the origin these myofibroblast the coexpression 
of FSP-1 or ǂSMA and CD31 was investigated by double immunostaining. They found that 
about 45% of the ǂSMA and 60% of the FSP-1 positive myofibroblast were CD31 positive, 
suggesting the endothelial origin of these cells. In accordance with Zeisberg et al. Li and 
coworkers revealed the contribution of EndMT in the development of STZ induced renal 
fibrosis. They developed a Tie2Cre; EGFP mice to trace the localization of the cells with 
endothelial origin in a mice model of STZ induced DN. Tie2 is a pan endothelial marker 
which is expressed in EC during embryogenesis and thereafter during adulthood. In the 
bigenic mice Cre recombinase is expressed under the promoter of Tie2 and mediates the 
excision of a loxP stop cassette thus activating the expression of EGFP. In accordance with 
other studies (Schlaeger et al., 1997; Koni et al., 2001; Limbourg et al., 2005) the Cre mediated 
recombination occurred mainly in the ECs, with only a little activity in other cells. In the 
normal kidneys of Tie2Cre; EGFP mice CD31 staining colocalized with the EGFP positive 
cells. However, 1 or 6 months after the induction of STZ induced DN 10.4% or 23.5% of renal 
ǂSMA positive interstitial myofibroblasts were EGFP positive, suggesting there endothelial 
origin. Apparently these studies clearly demonstrate the significant role of EndMT in the 
pathomechanism of renal fibrosis. However, ECs are specialized squamous epithelium and 
the similarities between EMT and EndMT is evident suggesting that EndMT is a specific 
form of EMT. So the question emerges why ECs can invade the basement membrane and 
become real interstitial myofibroblasts if epithelial cells can not.  
4.3 Pericytes, perivascular cells or resident fibroblasts 
The definition of pericytes (also known as Rouget cells), perivascular cells or resident 
fibroblasts in the kidney is still a matter of debate.  Pericytes occurs around peritubular 
capillaries and postcapillary venules in the kidney. Pericytes characteristically line at the 
outer surface of EC and are covered fully or in part with capillary basement membrane thus 
fulfilling the major criterias of pericytes. These gaps of capillary basement membrane are 
frequently colocalise with the projections of pericytes, which are believed to be sites of 
intercellular communication (Grgic et al., 2011). Some projections of the pericytes also can 
reach the basement membrane of the TECs, make them similar or identical to the cells called 
resident fibroblast (Kaissling et al., 1996). Recently it has been suggested that activation of 
pericytes - which are relatively undifferentiated cells - may led to phenotype transformation 
of them into myofibroblasts. To investigate the potential role of pericytes as myofibroblast 
precursors Lin et al. generated a transgenic mice expressing GFP under the promoter of 
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collagen type I, ǂ1 (Lin et al., 2008). In these animals the presence of GFP labels, with high 
sensitivity, the collagen I, ǂ1 producing cell. In healthy kidney of this, coll1a1-GFP mice 
peritubular capillaries were lined intermittently with collagen type I, ǂ1 producing cells, 
which were subendothelial in a direct apposition with CD31 positive ECs and exhibited 
pedicle like attachment plaques suggesting the direct interaction of collagen type I, ǂ1 
producing cells with the ECs. These characteristics define these collagen type I, ǂ1 
producing cells as pericytes. In developed, but young, 12 days old animals the majority 
(98,4%) of these cells also expressed chondroitin sulfate proteoglycan 4 (CSPG4), ǂSMA and 
PDGFRǃ which are all known markers of pericytes. Later in healthy adult mice renal 
pericytes lost their CSPG4 and ǂSMA positivity with time. To investigate the contribution of 
the pericytes to renal fibrosis Lin et al. induced UUO in these coll1a1-GFP mice. In the 
kidney of diseased mice pericytes do not lose their CSPG4, ǂSMA and PDGFRǃ positivity, 
rather their population expands. In this model of renal fibrosis 7 days after ureteral 
obstruction there was a close but imperfect correlation between the collagen 1, ǂ1producing 
(GFP+) and ǂSMA positive interstitial cells. Actually 1% of the GFP producing cell did not 
express ǂSMA and 25% of the ǂSMA producing cells did not express GFP in the renal 
interstitium. These study of Lin et al. strongly suggest that the main source of the 
myofibroblasts are the collagen I, ǂ1 producing cells, most likely pericytes in the obstructed 
kidneys. However, these data also suggest that a remarkable percent of the ǂSMA 
producing myofibroblasts may originate from other cells then pericytes. Later this group to 
strengthen their observations made a genetic fate mapping study to test that pericytes are 
the primary source of myofibroblasts in the UUO model of fibrosis. Humphreys et al. 
developed a transgenic Cre driver mice that express bacterial Cre recombinase under the 
regulation of forkhead box D1 (FoxD1) promoter (Fig.6.) (Humphreys et al., 2010). FoxD1 is 
a transcriptional factor that is transiently expressed during development in metanephric 
mesenchyme cells that are fated to become mesangial, vascular smooth muscle cells and 
pericytes. These transgenic mice were then bred with R26R reporter mice. In the kidney of 
the FoxD1-Cre; R262 bigenic mice mesangial and vascular smooth muscle cells and many 
PDGFRǃ positive interstitial pericytes were detectable after X-gal staining. Fourteen days 
after UUO they found a marked expansion of LacZ positive cells in the interstitium of the 
injured kidneys. These ǃ galactosidase positive cells were ǂSMA positive and all SMA 
positive cells exhibited ǃ galactosidase activity as well. Suggesting that there was no 
significant population of cells becoming myofibroblast, except the previously FoxD1 
positive cells. However, following UUO FoxD1 transcripts were detected in the kidney 
samples of FoxD1-Cre; R262 bigenic mice. This means that not only the cells with the 
heritable marker of R26R mice, but also the de novo FoxD1 expressing cells are labeled with 
ǃ galactosidase. To circumvent this problem Humphreys B.D. et al developed FoxD1-GCE 
transgen mice, in which Cre recombinase is expressed under FoxD1 promoter in a 
tamoxifen-inducible manner. These mice were then bred with R26R reporter mice. FoxD1-
GCE; R26R mice that received tamoxifen during the nephrogenesis had ǃ galactosidase 
positive cells in the renal interstitium which also expressed PDGFRǃ and were negative for 
ǂSMA (myofibroblast), CD31 (endothelial cell) or F4/80 (macrophages) defining them as 
pericytes. However, it should be noted that in FoxD1-GCE; R26R mice approximately 20% of 
pericytes were labeled with ǃ galactosidase activity. Ten days after UUO all ǃ galactosidase 
positive interstitial cells remained PDGFRǃ positive and acquired expression of ǂSMA 
demonstrating that pericytes differentiated into myofibroblast. Nowadays the most 
accepted theory is the transformation of perycites into myofibroblasts. However, since these 
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experiments are rather new it is still not known how the traditional fibrosis inducing factors 
like TGFǃ-1 or Angiotensin can alter the ECM producing capacity of myofibroblasts derived 
from perycites.   
 
 
Fig. 6. Fourteen days after UUO a marked expansion of ǃ galactosidase positive cells (blue) 
was observed in the interstitium of the injured FoxD1-GC; R26R mouse kidneys. Merged 
light and fluorescence image show the co-expression of ǃ galactosidase (blue) with SMA 
(red) after UUO day 14. (After Humphreys et al., 2010). 
4.4 Bone marrow derived fibrocytes 
Fibrocytes are bone marrow (BM) derived mesenchymal cells (Mori et al., 2005; Kisseleva et 
al., 2006) that express the markers of hematopoietic stem cells, monocytes and fibroblasts 
(Yang  et al., 2002; Mori et al., 2005; Abe et al., 2001). Previously these CD14+ and CD16- 
fibrocyte precursors were termed as inflammatory monocytes (Gordon & Taylor, 2005). In 
response to tissue damage these cells are released in high number from the BM and then 
migrate into the site of the injury. In the tissue most of these inflammatory monocytes then 
believed to differentiate into macrophages, dendritic cells (Tacke & Randolph, 2006). 
However, a subpopulation of these CD14+ and CD16- cells can differentiate into other cells 
types, such as myoblasts, osteoblasts, epithelial, endothelial, neuronal cells (Zhao et al., 2003; 
Kuwana et al., 2003) or fibrocytes as an intermediate stage of differentiation into mature 
myofibroblasts. In vitro the co-culture of the CD14+ fibrocyte progenitors with T cells or 
stimulation of them with TGFǃ1, PDGF, IL-4 or IL-13 promotes their maturation into 
fibrocytes. By contrast aggregated IgG, serum amyloid P, INFǄ or IL-12 inhibits the 
differentiation of CD14+ mononuclear cells into fibrocytes. Fibrocytes express CD34 and 
CD105 hematopoietic stem cell markers and MHC I and MHC II and the costimulatory 
molecules CD80 and CD86. Today the presence of CD45, CD34, or other myeloid antigen 
like CD11b and CD13 is considered to discriminate fibrocytes from leukocytes. Fibrocytes 
still do not express large amount of ECM (Chesney et al., 1998), however they produce ECM 
degrading enzymes, such as MMP9 (García-de-Alba et al., 2010). Fibrocytes can differentiate 
into myofibroblast in vivo (Mori et al., 2005; Schmidt et al., 2003). The further differentiation 
of the fibrocytes into myofibroblasts is stimulated by TGFǃ1 and endothelin-1. The matured 
myofibroblasts then produce significantly more collagen then fibrocytes and express ǂSMA. 
Myofibroblasts also lose the CD34 and CD45 markers of fibrocytes. Despite our huge 
knowledge about the differentiation of CD14+ mononuclear cells into myofibroblast, the 
contribution of these BM derived cells to the population of myofibroblast is generally 
Eosin, ǃ galactosidase                  ǃ galactosidase              ǂSMA 
 
www.intechopen.com
 Renal Failure – The Facts 
 
68
believed to be small. To investigate the contribution of fibrocytes to the population of 
myofibroblast Iwano M. et al. generated transgenic mice, in which EGFP is expressed under 
the promoter of FSP-1. In this experiment they used FSP-1 as marker of myofibroblast 
(Iwano M et al., 2002). The T cell depleted BM of these transgenic mice was intravenously 
injected into lethally irradiated Balb/c, wild type recipients. Thirty days after the BM 
transfer the chimeric mice underwent UUO. Finally, 10 days after the UUO the number of 
FSP-1 and EGFP double positive BM derived cells were counted in the injured and in the 
collateral, normal kidney samples. By counting several random cortical fields they found 
that about the 12% of the renal FSP-1 positive cells have BM origin in the normal and about 
15% in the injured kidneys. These data suggest that 10 days after UUO only 3% of the FSP-1 
positive myofibroblasts are originated from the BM. Others investigating the contribution of 
fibrocytes to the population of myofibroblast have found similar results. Lin et al. 
transplanted the BM cells of coll1a1-GFP mice into a lethally irradiated wild type recipient 
mice. In these chimeric mice all collagen type I, ǂ1 producing cell with BM origin express 
GFP. To induce renal fibrosis UUO was performed on these chimeric mice. Interestingly, 
they found that 7 days after UUO only the 0.1% of the myofibroblast expressed the CD34 
and CD45 markers of fibrocytes (Abe et al., 2001) in the chimeric mice. Taken together these 
data suggest that the contribution of CD14+ CD16- BM cells to the population of 
myofibroblasts is not significant. One week after the UUO only a few percent (0.1-3%) of the 
myofibroblasts are originated from these CD14+ CD16- BM cells. 
5. Summary and concluding remarks 
Today there are different theories about the possible origin of the myofibroblasts that are 
responsible for scar formation in the injured kidney. A hypothesis that recently became 
popular is the mesenchymal transition of the renal tubular epithelial cells. During EMT 
epithelial cells undergo phenotypic conversion, which means that they lose their polarity, 
epithelial adhesion properties and starts the de novo synthesis of ǂSMA and other 
mesenchymal factors. This process is already well known in different physiological and 
pathological processes, notably in embryogenesis and carcinogenesis. In vitro experiments 
on different epithelial cell lines and on primer epithelial cells strongly suggest the existence 
of EMT based on their increased expression of ǂSMA, vimentin and decreased expression of 
E-cadherin. However, the role of EMT is controversial in renal fibrosis. Recently, 
Humphreys et al. using double transgenic animals, clearly demonstrated that tubular 
epithelial cells can not invade the basement membrane, suggesting that EMT does not lead 
to formation of myofibroblasts, actually not in vivo in the mice model of UUO. Interestingly, 
the concept of EndMT is widely accepted, despite that the endothelial cells are specialized 
squamous type epithelial cells suggesting that EndMT is only a specific form of EMT. 
Actually, the similarities between EMT and EndMT is evident. During the phenotype 
conversion endothelial or epithelial cells lose their original markers and start to express 
mesenchymal ones, such as ǂSMA. However, the question why endothelial cells can invade 
the basement membrane and epithelial cells can not is still unanswered. Today, perhaps the 
most accepted theory about the possible origin of myofibroblasts is the transformation of 
perycites into myofibroblasts. This observation is rather new and it is still not known how 
the traditional fibrosis inducing factors like TGFǃ or angiotensin can alter the ECM 
producing capacity of myofibroblasts derived from perycites. Finally the contribution of 
CD14+ CD16- BM cells to the population of myofibroblasts is not significant. These cells are 
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responsible for only 1-2% of the myofibroblast. There estimated number of patients with 
chronic kidney disease is over 2.5 millions in Europe and the number of patients on chronic 
renal replacement therapy number is continuously increasing. Thus research in that field 
has not only scientific impact, but has also important implications on general health and 
health care systems considering the quality of life in uremia and the socio-economic costs of 
renal replacement therapies. Actually regardless of the initiating cause (infection, 
autoimmune response, chemical insult, radiation or tissue injury etc.) fibrosis is the final 
common pathway for all progressive renal diseases. That is why it is so important to 
understand the complex interplay among immune cells, myofibroblasts precursors and renal 
cells. The development of new antifibrotic therapies is getting more and more important, and 
it requires the understanding of the cellular origin and precise role of myofibroblasts.  
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